Published in Histopathology on May 01, 2000
The histological diagnosis of metastases to the breast from extramammary malignancies. J Clin Pathol (2007) 1.44
Resectable pancreatic small cell carcinoma. Rare Tumors (2011) 1.11
Aspartic proteinase napsin is a useful marker for diagnosis of primary lung adenocarcinoma. Br J Cancer (2003) 1.05
Small-cell neuroendocrine carcinoma of the breast. J Clin Pathol (2006) 1.04
Extrapulmonary small cell carcinoma of the liver: clinicopathological and immunohistochemical findings. Yonsei Med J (2007) 1.04
Large cell neuroendocrine carcinoma of the larynx: definition of an entity. Head Neck Pathol (2010) 0.96
Primary small cell carcinoma of the breast with TTF-1 and neuroendocrine marker expressing carcinoma in situ. Int J Clin Exp Pathol (2010) 0.93
Ancillary testing in lung cancer diagnosis. Pulm Med (2012) 0.92
Primary colorectal small cell carcinoma: a clinicopathological and immunohistochemical study of 10 cases. Diagn Pathol (2007) 0.88
Expression of thyroid transcription factor 1 in primary brain tumours. J Clin Pathol (2004) 0.87
Endoscopic ultrasound-guided fine-needle aspiration of metastases to the pancreas: A study of 25 cases. Cytojournal (2011) 0.85
TTF1 expression in normal lung neuroendocrine cells and related tumors: immunohistochemical study comparing two different monoclonal antibodies. Virchows Arch (2010) 0.84
Comparison of metastatic neuroendocrine neoplasms to the breast and primary invasive mammary carcinomas with neuroendocrine differentiation. Mod Pathol (2016) 0.83
TTF-1 positive small cell cancers: Don't think they're always primary pulmonary! World J Gastrointest Oncol (2011) 0.83
CDX2 as a marker of intestinal EC-cells and related well-differentiated endocrine tumors. Virchows Arch (2004) 0.82
Value of napsin A and thyroid transcription factor-1 in the identification of primary lung adenocarcinoma. Oncol Lett (2010) 0.82
Neuropathology of brain metastases. Surg Neurol Int (2013) 0.82
Cutaneous metastasis from pulmonary large cell neuroendocrine carcinoma in the scalp. Int J Clin Exp Pathol (2014) 0.81
Uveal metastasis 43 years after resection of bronchogenic carcinoid. Br J Ophthalmol (2002) 0.78
Extrapulmonary small cell carcinoma: involvement of the brain without evidence of extracranial malignancy by serial PET/CT scans. World J Surg Oncol (2008) 0.78
Expression of MMP-10, MMP-21, MMP-26, and MMP-28 in Merkel cell carcinoma. Virchows Arch (2009) 0.77
Expression of thyroid transcription factor-1 in normal endometrium is associated with risk of endometrial cancer development. Mod Pathol (2012) 0.76
Efficacy of topotecan in pretreated metastatic poorly differentiated extrapulmonary neuroendocrine carcinoma. Cancer Med (2016) 0.75
Distinct Characteristics of Small Cell Lung Cancer Correlate With Central or Peripheral Origin: Subtyping Based on Location and Expression of Transcription Factor TTF-1. Medicine (Baltimore) (2015) 0.75
Primary neuroendocrine (Merkel cell) carcinoma of the nipple. Virchows Arch (2002) 0.75
Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat Med (1997) 2.88
Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer (2008) 2.67
ALCAM/CD166 is overexpressed in colorectal carcinoma and correlates with shortened patient survival. J Clin Pathol (2004) 2.45
Acute right-sided heart failure due to hemorrhage into a pericardial cyst. Ann Thorac Surg (1997) 2.24
European and US publications in the 50 highest ranking pathology journals from 2000 to 2006. J Clin Pathol (2007) 2.20
Overexpression of the death-promoting gene bax-alpha which is downregulated in breast cancer restores sensitivity to different apoptotic stimuli and reduces tumor growth in SCID mice. J Clin Invest (1996) 2.00
Patterns of chromosomal imbalances in adenocarcinoma and squamous cell carcinoma of the lung. Cancer Res (1997) 1.89
Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res (1996) 1.82
Caveolin-1 is down-regulated in human ovarian carcinoma and acts as a candidate tumor suppressor gene. Am J Pathol (2001) 1.67
Chromosomal alterations in the clonal evolution to the metastatic stage of squamous cell carcinomas of the lung. Br J Cancer (2000) 1.65
Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis (1989) 1.64
Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas. Am J Clin Pathol (2001) 1.62
Subcutaneous crystal-storing histiocytosis associated with lymphoplasmacytic lymphoma (immunocytoma) Pathol Res Pract (1996) 1.57
CD24 is an independent prognostic marker of survival in nonsmall cell lung cancer patients. Br J Cancer (2003) 1.49
Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J Natl Cancer Inst (1999) 1.46
Quality indicators in breast cancer care. Eur J Cancer (2010) 1.46
Telemicroscopy via the internet. Nature (1998) 1.44
Small-cell lung cancer is characterized by a high incidence of deletions on chromosomes 3p, 4q, 5q, 10q, 13q and 17p. Br J Cancer (1997) 1.44
Down-regulation of caveolin-1, a candidate tumor suppressor gene, in sarcomas. Am J Pathol (2001) 1.43
[Inter-disciplinary European guidelines on surgery of severe obesity]. Vnitr Lek (2008) 1.42
GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics. Br J Cancer (2008) 1.41
Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma. Br J Cancer (2004) 1.39
Patterns of chromosomal imbalances in invasive breast cancer. Int J Cancer (2000) 1.38
High expression of RelA/p65 is associated with activation of nuclear factor-kappaB-dependent signaling in pancreatic cancer and marks a patient population with poor prognosis. Br J Cancer (2007) 1.37
Thyroid transcription factor-1 is the superior immunohistochemical marker for pulmonary adenocarcinomas and large cell carcinomas compared to surfactant proteins A and B. Histopathology (2000) 1.36
Spectrum of congenital heart defects and extracardiac malformations associated with chromosomal abnormalities: results of a seven year necropsy study. Heart (1999) 1.33
Increased expression of epidermal fatty acid binding protein, cofilin, and 14-3-3-sigma (stratifin) detected by two-dimensional gel electrophoresis, mass spectrometry and microsequencing of drug-resistant human adenocarcinoma of the pancreas. Electrophoresis (1999) 1.30
Expression of AGR2 in non small cell lung cancer. Histol Histopathol (2007) 1.26
Prognostic factors for adenoid cystic carcinoma of the head and neck: a retrospective evaluation of 96 cases. J Oral Pathol Med (1990) 1.20
Cytoplasmic overexpression of ALCAM is prognostic of disease progression in breast cancer. J Clin Pathol (2006) 1.17
Genomic alterations associated with malignancy in head and neck cancer. Head Neck (1998) 1.17
A haemorrhagic fever from the Côte d'Ivoire. Lancet (1999) 1.17
Immunohistochemical differentiation of metastatic breast carcinomas from metastatic adenocarcinomas of other common primary sites. Histopathology (1996) 1.16
Primary small-cell lung carcinomas and their metastases are characterized by a recurrent pattern of genetic alterations. Int J Cancer (1997) 1.16
Distinct patterns of chromosomal alterations in high- and low-grade head and neck squamous cell carcinomas. Cancer Res (1996) 1.14
[Her2 testing in gastric cancer. What is different in comparison to breast cancer?]. Pathologe (2010) 1.14
Identification of novel proteins associated with the development of chemoresistance in malignant melanoma using two-dimensional electrophoresis. Electrophoresis (2000) 1.14
SPARC expression in resected pancreatic cancer patients treated with gemcitabine: results from the CONKO-001 study. Ann Oncol (2014) 1.13
The PI3K inhibitor LY294002 blocks drug export from resistant colon carcinoma cells overexpressing MRP1. Oncogene (2006) 1.13
Patterns of chromosomal alterations in metastasizing and nonmetastasizing primary head and neck carcinomas. Cancer Res (1997) 1.09
Cell lines derived from human ovarian carcinomas: growth stimulation by gonadotropic and steroid hormones. J Natl Cancer Inst (1983) 1.08
Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma. Ann Hematol (2000) 1.07
Uterine tumor resembling ovarian sex-cord tumor--a case report and review of the literature. Virchows Arch (2001) 1.07
Tyrosinase, melan-A, and KBA62 as markers for the immunohistochemical identification of metastatic amelanotic melanomas on paraffin sections. Mod Pathol (1998) 1.07
Co-expression and prognostic value of gross cystic disease fluid protein 15 and mammaglobin in primary breast cancer. Histol Histopathol (2007) 1.07
In vitro growth promotion of human mammary carcinoma cells by steroid hormones, tamoxifen, and prolactin. J Natl Cancer Inst (1984) 1.06
Human papilloma virus status and chromosomal imbalances in primary cervical carcinomas and tumour cell lines. Eur J Cancer (2000) 1.05
Uroplakin III is a highly specific and moderately sensitive immunohistochemical marker for primary and metastatic urothelial carcinomas. Am J Clin Pathol (2000) 1.03
DFNA5 (ICERE-1) contributes to acquired etoposide resistance in melanoma cells. FEBS Lett (2001) 1.03
Distinct regions of allelic imbalance on chromosome 10q22-q26 in squamous cell carcinomas of the lung. Oncogene (1998) 1.02
Chromosome alterations in breast carcinomas: frequent involvement of DNA losses including chromosomes 4q and 21q. Br J Cancer (1998) 1.02
Morphological detection and quantification of lipoprotein(a) deposition in atheromatous lesions of human aorta and coronary arteries. Virchows Arch A Pathol Anat Histopathol (1990) 1.01
A snapshot of microarray-generated gene expression signatures associated with ovarian carcinoma. Int J Gynecol Cancer (2008) 1.00
Stereoisomers of calcium antagonists which differ markedly in their potencies as calcium blockers are equally effective in modulating drug transport by P-glycoprotein. Biochem Pharmacol (1992) 1.00
[The UICC Telepathology Consultation Center. "Second opinion" over the Internet for pathologists]. Pathologe (2001) 0.99
[Necessity of increasing autopsy frequency following the introduction of DRGs]. Pathologe (2007) 0.99
Multivariate analysis of oestrogen receptor alpha, pS2, metallothionein and CD24 expression in invasive breast cancers. Br J Cancer (2006) 0.97
Utility of 123C3 monoclonal antibody against CD56 (NCAM) for the diagnosis of small cell carcinomas on paraffin sections. Hum Pathol (1997) 0.97
Personalized cancer medicine and the future of pathology. Virchows Arch (2011) 0.97
Identification of differentially expressed genes in human melanoma cells with acquired resistance to various antineoplastic drugs. Int J Cancer (2000) 0.96
Overexpression of c-erbB2 protein correlates with disease-stage and chromosomal gain at the c-erbB2 locus in non-small cell lung cancer. Eur J Cancer (2001) 0.96
Cancer beyond organ and tissue specificity: next-generation-sequencing gene mutation data reveal complex genetic similarities across major cancers. Int J Cancer (2014) 0.95
Influence of vitamin D3, 1,25-dihydroxyvitamin D3, and 24,25-dihydroxyvitamin D3 on parathyroid hormone secretion, adenosine 3',5'-monophosphate release, and ultrastructure of parathyroid glands in organ culture. Endocrinology (1979) 0.94
Involvement of the DNA mismatch repair system in antineoplastic drug resistance. J Cancer Res Clin Oncol (1999) 0.94
Antigenicity testing by immunohistochemistry after tissue oxidation. J Clin Pathol (2007) 0.93
Allelic loss on chromosome 10q in human lung cancer: association with tumour progression and metastatic phenotype. Br J Cancer (1998) 0.93
Endogenous myoglobin in human breast cancer is a hallmark of luminal cancer phenotype. Br J Cancer (2010) 0.93
Expression of lysophosphatidic acid acyltransferase beta (LPAAT-beta) in ovarian carcinoma: correlation with tumour grading and prognosis. Br J Cancer (2005) 0.92
Genetic imbalances with impact on survival in colorectal cancer patients. Histopathology (2003) 0.92
RNA-based determination of ESR1 and HER2 expression and response to neoadjuvant chemotherapy. Ann Oncol (2012) 0.91
Modulation of DNA topoisomerase II activity and expression in melanoma cells with acquired drug resistance. Br J Cancer (2000) 0.91
[Immunohistochemical diagnosis in cancer metastasis of unknown primary tumor]. Pathologe (2002) 0.91
Cloning and characterization of human cDNAs encoding a protein with high homology to rat intestinal development protein OCI-5. Gene (1997) 0.90
Antigen detection by the monoclonal antibodies CA 19-9 and CA 125 in normal and tumor tissue and patients' sera. J Cancer Res Clin Oncol (1986) 0.90
Identification of allelic losses in benign, borderline, and invasive epithelial ovarian tumors and correlation with clinical outcome. Cancer (1997) 0.90
[Genetic screening of head-neck carcinomas using comparative genomic hybridization (CGH)]. Laryngorhinootologie (1996) 0.90
[Study of efficiancy of teleconsultation: the Telepathology Consultation Service of the Professional Assoziation of German Pathologists for the screening program of breast carcinoma]. Verh Dtsch Ges Pathol (2005) 0.88
Image analysis for comparative genomic hybridization based on a karyotyping program for windows. Anal Quant Cytol Histol (1997) 0.88
High-dose rate interstitial with external beam irradiation for localized prostate cancer--results of a prospective trial. Radiother Oncol (1998) 0.88
Induction of transforming growth factor beta by the antiestrogens droloxifene, tamoxifen, and toremifene in MCF-7 cells. Am J Clin Oncol (1991) 0.88
Time gated fluorescence spectroscopy in Barrett's oesophagus. Gut (2003) 0.87
Expression of DNA repair proteins hMSH2, hMSH6, hMLH1, O6-methylguanine-DNA methyltransferase and N-methylpurine-DNA glycosylase in melanoma cells with acquired drug resistance. Int J Cancer (1999) 0.86
Decreased drug accumulation in a mitoxantrone-resistant gastric carcinoma cell line in the absence of P-glycoprotein. Int J Cancer (1997) 0.86
Enhanced expression of human ABC-transporter tap is associated with cellular resistance to mitoxantrone. FEBS Lett (2001) 0.86
Actinomycotic inflammatory disease and misdiagnosis of ovarian cancer. A case report. Anticancer Res (2006) 0.86
Immunohistochemical differentiation of metastases of renal carcinomas versus other carcinomas with anti-gamma GT monoclonal antibody 138H11. Histopathology (1997) 0.86
Expression of aminopeptidase N/CD13 in human ovarian cancers. Int J Gynecol Cancer (2006) 0.86
Topoisomerase 1A, HER/2neu and Ki67 expression in paired primary and relapse ovarian cancer tissue samples. Histol Histopathol (2006) 0.85
Search for novel proteins involved in the development of chemoresistance in colorectal cancer and fibrosarcoma cells in vitro using two-dimensional electrophoresis, mass spectrometry and microsequencing. Electrophoresis (1999) 0.84
Selection and characterization of a high-activity ribozyme directed against the antineoplastic drug resistance-associated ABC transporter BCRP/MXR/ABCG2. Cancer Gene Ther (2001) 0.84
Specificity of PCR-based clonality analysis of immunoglobulin heavy chain gene rearrangements for the detection of bone marrow involvement by low-grade B-cell lymphomas. J Pathol (2000) 0.84
Paget's disease of the vulva with underlying apocrine adenocarcinoma and local lymph node invasion. Pathol Res Pract (1981) 0.84
[PCR based diagnosis in pathology]. Pathologe (2000) 0.84
[Modern fetal autopsy oriented to clinical demands using technical information methods]. Pathologe (1997) 0.83
Anterior gradient protein 2 (AGR2) is an independent prognostic factor in ovarian high-grade serous carcinoma. Virchows Arch (2012) 0.83
Effect of the breast-cancer resistance protein on atypical multidrug resistance. Lancet Oncol (2000) 0.83
Microsatellite alterations in serum DNA of patients with colorectal cancer. Lab Invest (1999) 0.83
Unfavourable prognostic significance of S100P expression in ovarian cancers. Histopathology (2007) 0.83
Borderline tumors of the ovary and peritoneal implants. Verh Dtsch Ges Pathol (2005) 0.83